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Abstract
Background: There is limited information available on cytokine profiles in dogs with different degrees of disease
severity due to natural infection of Leishmania infantum. The aim of this study was to investigate L. infantum-specific
IFN-γ and IL-10 production in blood from dogs with leishmaniosis at diagnosis and correlate these findings with
disease severity, humoral immune response and blood parasitemia.
Methods: Sixty dogs were diagnosed based on physical examination, routine laboratory tests, L. infantum-specific
antibody levels measured by quantitative ELISA and blood parasitemia by real-time PCR. Heparin whole blood was
stimulated with L. infantum soluble antigen (LSA) and concanavalin A (ConA) and incubated for 5 days. IFN-γ and IL-10
concentrations were measured in supernatants with sandwich ELISAs.
Results: The majority of dogs (n = 36) were classified as LeishVet stage II (moderate disease). The rest of the dogs were
classified as stage I (n = 10), III (n = 10) and IV (n = 4). Dogs classified with stage I and IIa presented significantly higher
(P = 0.02) LSA IFN-γ concentrations, lower (P <0.0001) antibody levels and a tendency for lower blood parasitemia
(P = 0.1) than dogs classified with stages IIb, III or IV while no differences in ConA IFN-γ or IL-10 concentrations were
observed among groups. Thirty-five dogs produced significantly higher LSA IFN-γ (mean ± SD: 2320 ± 3960 pg/ml) and
ConA IFN-γ (mean ± SD: 7887 ± 7273 pg/ml) when compared with 25 dogs that did not produce detectable LSA IFN-γ
but produced ConA IFN-γ (mean ± SD: 4917 ± 5233 pg/ml). IFN-γ producer dogs presented lower (mean ± SD: 5750 ±
14,082 ELISA units (EU), P = 0.001) antibody levels and blood parasitemia (mean ± SD: 5 ± 10 parasites/ml, P = 0.001)
when compared with IFN-γ non-producers (mean ± SD: 19,638 ± 28,596 EU and 1100 ± 5112 parasites/ml), respectively.
LSA IL-10 was not detectable in 34 dogs while 49 dogs secreted ConA IL-10 (mean ± SD of 90 ± 103 pg/ml). LSA IFN-γ
concentration was negatively correlated with blood parasitemia and antibody levels and positively correlated with
ConA IFN-γ and LSA IL-10 concentrations.
Conclusions: The results of this study demonstrate that sick dogs lacking L. infantum specific IFN-γ production in
stimulated whole blood produce a strong humoral response, have a high blood parasitemia and severe clinical disease.
IL-10 does not appear to be a marker of disease severity.
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Background
Species of Leishmania are obligate intracellular proto-
zoan parasites that are transmitted by female phleboto-
mine sandflies. Canine leishmaniosis is a zoonotic
disease caused by several species of Leishmania. Al-
though other Leishmania species have been reported to
infect dogs such as L. major [1], L. tropica and L. brazi-
liensis [2–4], Leishmania infantum is the most common
species in the Mediterranean basin [5, 6]. Dogs are con-
sidered the principal reservoir for leishmaniosis in
people due to L. infantum in the Mediterranean
basin, Middle East and South America [5].
Both innate and adaptive immune responses play a role
in the outcome of Leishmania infection. Classically, the
major role against the parasite is played by the adaptive
immune response, characterized by the balance between
T-helper 1 (Th1) and T-helper 2 (Th2) response. Th1
secrete interleukin-2 (IL-2), TNF-alpha and interferon-
gamma (IFN-γ) and this response is associated with
controlling infection while Th2 cells secrete interleukin-4
(IL-4), interleukin-5 (IL-5), interleukin-10 (IL-10), and
transformation growth factor beta (TGF-β) and correlate
with disease progression [7, 8].
Dogs show a broad range of clinical manifestations
and immune responses [9] in canine leishmaniosis.
Canine L. infantum infection can manifest as a chronic
subclinical infection, self-limiting disease, or non-self-
limiting illness [5, 6] as in humans [10]. In addition, sev-
eral degrees of disease severity are found in dogs ranging
from mild disease to severe fatal disease with different
clinical outcomes, prognosis and treatment options.
Therefore, a clinical staging system is currently used in
the clinical setting [6]. The two extremes of this clinical
spectrum are characterized by: (1) “Resistant” healthy
dogs with a protective CD4+ T-cell-mediated immune
response characterized by production of Th1 cytokines-
like such as IFN-γ, IL-2 and TNF-α, which induce
anti-Leishmania activity by apoptosis of parasites in
macrophages via nitric oxide (NO) metabolism [11], and
(2) sick dogs which are characterized by a marked humoral
immune response, absent or reduced cell mediated im-
munity with high levels of IL- 10 and TGF-β and high
parasite burden, which is detrimental to the animal [5, 12].
Unfortunately, there are few and poorly standardized
assays to evaluate T-cell mediated immunity responses
[13] such as leishmanin skin test [14, 15] and lympho-
cyte proliferation [16, 17] in the dog. The results of cyto-
kine profiles in canines with L. infantum infection are
frequently limited and fragmentary [9]. Cytokines in-
cluding IFN-γ and IL-10 have been studied in several
organs with different techniques in dogs with poorly
defined clinical classification and different states of
infection [5, 9]. In addition, cytokines have been mainly
investigated in vaccinated [18] or in experimentally-
infected dogs [17] but limited information is available in
sick dogs with different degrees of disease severity due
to L. infantum natural infection [17, 19]. The aim of this
study was to investigate L. infantum-specific IFN-γ and
IL-10 production in stimulated blood in dogs with clin-
ical leishmaniosis at the time of diagnosis and correlate
these with disease severity, the humoral immune re-
sponse and blood parasitemia.
Methods
Dogs
Sixty dogs with clinical leishmaniosis were prospectively
enrolled from January 2014 to February 2016 at the time
of diagnosis. The dogs were from different Catalonian and
Balearic veterinary centers from Spain: Fundació Hospital
Clínic Veterinari (Bellaterra, Barcelona), Hospital Ars
Veterinaria (Barcelona), Hospital Mediterrani Veterinaris
(Reus, Tarragona), Consultori Montsant (Falset,
Tarragona) and Hospital Mon Veterinari (Manacor, Ma-
llorca). The diagnosis of canine leishmaniosis was made
based on the results of the physical examination, a
complete blood count (CBC) using Siemens Advia 120
Haematology System (Siemens Healthcare GmbH,
Germany), a biochemical profile including creatinine,
urea, total proteins, ALT and total cholesterol by Olympus
AU400 Chemistry Analyzer (CLIAwaived, USA), protein
serum electrophoresis by Hydrasys® (Sebia Electrophor-
esis, USA), urinalysis with urinary protein/creatinine ratio
(UPC) and quantitative serology for the detection of L.
infantum specific antibodies by means of a serial dilution
in house ELISA [20–22]. Cytological evaluation of any le-
sion or cutaneous histology and/or immunohistochemis-
try for Leishmania was also performed in some cases as
described elsewhere when needed [23]. In addition, DNA
was extracted from blood samples and L. infantum real-
time PCR (RT-PCR) was performed with an absolute
quantification as previously described [22, 24]. Dogs were
classified in four clinical stages (stage I-mild disease, II-
moderate disease including substages IIa and IIb, III-
severe disease and IV-very severe disease) at the time
of diagnosis as previously described [6].
Whole blood assay
The leucocyte concentration including lymphocyte and
neutrophil concentrations was very similar between dogs
measured by a CBC. Heparinized blood was diluted to a
ratio of 1:10 with Rosewell Park Memorial Institute (RPMI)
1640 medium with stable glutamine and 25 mM hepes
(Biowest®, USA) supplemented with 60 μg/ml of penicillin,
100 μg/ml streptomycin (Life Technologies™, USA) and
10 % Fetal Bovine Serum Premium South America Origin
(Biowest®, USA). Five hundred μl of heparinized blood was
mixed with 4.5 ml of complete medium as described above
per each well and incubated in 12-well flat bottom
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plastic culture plates 3596 (Costar® Corning, NY,
USA). Three different treatment conditions were
established: (i) medium alone; (ii) medium with L.
infantum soluble antigen (LSA) at a concentration of
10 μg/ml provided by Dr. Cristina Riera (Facultat de
Farmacia, Universitat de Barcelona); and (iii) medium
with mitogen concanavalin A (ConA) (100 mg Medi-
cago®, Sweden) at a concentration of 10 μg/ml. The
plates were incubated for 5 days at 37 °C in 5 % of
CO2 air. Following incubation, blood was centrifuged
at 300 g for 10 minutes and the supernatant was col-
lected and stored at -80 °C until used.
Sandwich ELISAs for the determination of IFN-γ and IL-10
Cytokine analysis of IFN-γ (n = 60) and IL-10 (n = 53)
were performed according to the manufacturer’s in-
structions (DuoSet® ELISA by Development System
R&DTM, UK) using 96 well cell flat bottom plates
(Costar® Corning, USA). Slight modifications were
done for the IFN-γ and IL-10 ELISAs. The standard
curve for IFN-γ started with 8000 pg/ml and two-fold
dilutions were made until 62.5 pg/ml concentration.
Standard curve for IL-10 started with 2000 pg/ml and
two-fold dilutions were made until 15.6 pg/ml concentra-
tion was obtained. Supernatants treated with ConA were
diluted 1:1 with reagent diluent. Duplicates of all
supernatants studied were performed in all ELISAs.
Optical density was measured with an ELISA reader
(Anthos 2020) at wavelength of 450 nm. The standard
curve for each cytokine was calculated using a com-
puter generated four parameter logistic curve-fit with
program MyAssays (http://www.myassays.com/). Plates
were repeated when R2-value of standard curve was below
0.98. Dogs were classified as IFN-γ producers when L.
infantum specific IFN-γ concentration was detectable
after subtracting medium alone. Dogs were classified as
IFN-γ non-producers when L. infantum specific IFN-γ
concentration subtracting medium alone was at not
detectable levels. IL-10 detectable concentrations were
considered after subtracting medium alone for LSA and
ConA stimulations.
Statistical analysis
The statistical analysis was performed using the SPSS
22.0 for Windows software (SPSS Inc., USA). A non-
parametric Mann-Whitney U-test was used to com-
pare groups. A non-parametric Wilcoxon signed-rank
test was used to compare paired continuous variables.
The Spearman’s correlation was used to evaluate dif-
ferences in cytokine production, the level of anti-
bodies and blood parasitemia of the dogs studied.
Differences were considered significant with a 5 %
significance level (P < 0.05).
Results
Description of clinical data of dogs, clinical staging and
specific L. infantum IFN-γ response classifications
Both sexes were represented by 25 females and 35 males.
The median of age was four years with a range from
five months to 12 years. Forty-four purebred dogs be-
longing to more than 25 breeds and 16 mixed breed
dogs were included.
Based on clinicopathological findings and serological
tests, the majority of dogs (n = 36) were classified as Leish-
Vet stage II (moderate disease) and this stage was further
divided into stage IIa (n = 27) and stage IIb (n = 9). The
rest of the dogs were classified as stage I (n = 10), stage III
(n = 10) and stage IV (n = 4). All dogs in stage I were diag-
nosed with papular dermatitis due to L. infantum and pre-
sented negative to low positive antibody levels. The rest of
dogs presented typical clinicopathological findings and
mainly medium to high positive antibody levels. The re-
sults of signalment, serology, clinical signs and laboratory
abnormalities observed in dogs with clinical leishmaniosis
classified in four clinical stages are shown in Table 1.
Thirty-five dogs (58 %) were classified as IFN-γ pro-
ducers. The clinical staging of these dogs was: nine dogs
had stage I (25.7 %), 17 dogs stage IIa (48.5 %), three
dogs stage IIb (8.5 %), five dogs stage III (14.2 %) and
one dog stage IV (2.8 %) (Fig. 1a). In contrast, 25 dogs
did not secrete IFN-γ after LSA stimulation. All 25 dogs
(42 %) were classified as IFN-γ non-producers. The clin-
ical staging of IFN-γ non-producers was as follows: one
dog (4 %) was classified as stage I; ten dogs as stage IIa
(40 %); six dogs as stage IIb (24 %); five dogs as stage III
(20 %) and three dogs (12 %) as stage IV (Fig. 1b).
Antibody response
The results of antibody levels based on clinical staging
and IFN-γ classification are shown in Tables 2 and 3. Dogs
classified with stage I and IIa presented significantly lower
antibodies (Mann-Whitney U-test: Z = -4.37, P < 0.0001)
(mean±SD: 4050 ± 9947 EU) than dogs classified with
stages IIb, III or IV (mean±SD: 23,580 ± 30,308 EU).
IFN-γ producer dogs (mean ± SD: 5750 ± 14,082 EU)
showed statistically significant lower levels of antibodies
(Mann-Whitney U-test: Z = -3.23, P = 0.001) when
compared with IFN-γ non-producer dogs (mean ± SD:
19,638 ± 28,596 EU) (Table 2).
Blood parasite load by real-time PCR
The results of blood parasitemia based on clinical
staging and IFN-γ classification are shown in Tables 2
and 3. Blood PCR was positive in 40 dogs (66.6 %) out of
59 dogs. In addition, dogs classified with stage I and IIa
group presented a tendency (Mann-Whitney U-test:
Z = -1.53, P = 0.1) for lower blood parasitemia (5.3 ± 10.2
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Table 1 Clinicopathological findings in dogs with clinical leishmaniosis based on LeishVet clinical staging [6]
Clinical staging Gender/median
[range] of age in
months
Serology Clinical signs (number of dogs/total
number of dogs, %)
Laboratory findings (number of dogs/








Papular dermatitis (10/10, 100 %) No abnormalities observed
IIa-moderate
disease (n = 27)
11 females and
16 males/51 [5–153]
Low to high positive
antibody levels
Cutaneous lesions (20/27, 74 %):
• Exfoliative dermatitis (9/27, 33 %)
• Ulcerative dermatitis (9/27, 33 %)
• Alopecia (7/27, 26 %)
• Nodular dermatitis (3/27, 11 %)
• Papular dermatitis (2/27, 7 %)
• Ischemic dermatopathy (1/27, 4 %)
Lymphadenomegaly (19/27, 70 %)
Weight loss (8/27, 30 %)
Fever (5/27, 19 %)
Ocular lesions (4/27, 15 %):
• Conjunctivitis (3/27, 11 %)
• Blepharitis (1/27, 4 %)
Lameness (4/27, 15 %)
Vomiting and/or diarrhea (2/27, 7 %)
Inspiratory dyspnea (1/27, 4 %)
Masseter myositis (1/27, 4 %)
Muscle atrophy (1/27, 4 %)
Epistaxis (1/27, 4 %)
Mild to moderate normocytic normochromic
non-regenerative anemia (8/26, 31 %; 3/26,
12 %, respectively)
Mild leukocytosis with mature neutrophilia
(2/26, 8 %)
Mild to moderate thrombocytopenia (2/26, 8 %)
Mild leucopenia with lymphopenia and
neutropenia (2/26, 8 %)
Hyperproteinemia (13/27, 48 %)
Hypergammaglobulinemia (14/27, 52 %)
Hyperbetaglobulinemia (15/27, 55 %)
Hypoalbuminemia (6/26, 23 %)
IIb-moderate
disease (n = 9)





Cutaneous lesions (7/9, 77 %):
• Exfoliative dermatitis (3/9, 33 %)
• Ulcerative dermatitis (3/9, 33 %)
• Alopecia (2/9, 22 %)
Lymphadenomegaly (6/9, 67 %)
Weight loss (5/9, 56 %)
Ocular lesions (4/9, 44 %):
• Conjunctivitis (2/9, 22 %)
• Bilateral blepharitis (2/9, 22 %)
Vomiting and/or diarrhea (3/9, 33 %)
Lethargy (2/9, 22 %)
Lameness and articular pain (1/9,
33 %)
Polyuria and polydipsia (1/9, 11 %)
Mild to moderate normocytic normochromic
non-regenerative anemia (6/9, 67 %; 2/9, 22 %,
respectively)
Mild leukocytosis with mild mature neutrophilia
(2/9, 22 %)
Lymphopenia (3/9, 33 %)
Hyperproteinemia (7/9, 77 %)
Hypergammaglobulinemia (9/9, 100 %)
Hyperbetaglobulinemia (6/9, 66 %)
Hypoalbuminemia (6/9, 66 %)
III-severe
disease (n = 10)





Lymphadenomegaly (7/10, 70 %)
Cutaneous lesions (6/10, 60 %):
• Exfoliative dermatitis (4/10, 40 %)
• Alopecia (1/10, 10 %)
• Ulcerative dermatitis (2/10, 20 %)
Weight loss (5/10, 50 %)
Ocular lesions (3/10, 30 %):
• Bilateral blepharitis (1/10, 10 %)
• Conjunctivitis (1/10, 10 %)
• Superficial keratitis (1/10, 10 %)
Lethargy and anorexia (2/10, 20 %)
Vomiting and/or diarrhea (2/10,
20 %)
Splenomegaly (2/10, 20 %)
Lameness and articular pain (1/10,
10 %)
Muscle atrophy (1/10, 10 %)
Epistaxis (1/10, 11 %)
Polyuria and polydipsia (1/10, 10 %)
Fever (1/10, 10 %)
Chronic weakness (1/10, 10 %)
Mild normocytic normochromic non-regenerative
anemia (6/9, 67 %)
Moderate regenerative anemia (2/9, 22 %)
Thrombocytosis (1/9, 11 %)
Mild thrombocytopenia (1/9, 11 %)
Mild leukocytosis with mature neutrophilia
(2/9, 22 %)
Mild leukopenia with lymphopenia and
neutropenia (1/9, 11 %)
Lymphopenia (1/9, 11 %)
Mild lymphocytosis (1/9, 11 %)
Hyperproteinemia (8/10, 80 %)
Hypergammaglobulinemia (9/10, 90 %)
Hyperbetaglobulinemia (9/10, 90 %)
Hypoalbuminemia (9/10, 90 %)
Proteinuria (UPC) (10/10, 100 %)
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parasites/ml) than dogs classified with stages IIb, III or IV
group (1255 ± 5464 parasites/ml).
Interestingly, 14 IFN-γ producer dogs and five IFN-γ
non-producers were negative by PCR at the time of
diagnosis. Twenty-one (60 %) out of 35 IFN-γ producer
dogs were positive by PCR at the time of diagnosis.
Nineteen (76 %) out of 25 IFN-γ non-producer dogs
were positive to PCR at the time of diagnosis. IFN-γ pro-
ducer dogs presented a statistically significant lower para-
sitemia (Mann-Whitney U-test: Z =-3.22, P = 0.001) when
compared with IFN-γ non-producers (Table 3).
IFN-γ
The results of ConA and L. infantum specific IFN-γ con-
centrations based on clinical staging and IFN-γ classifica-
tion are shown in Tables 2 and 3. IFN-γ concentrations in
supernatants of blood stimulated with LSA and ConA
from all dogs studied were (mean ± SD) 1354 ± 3220 pg/
ml and 6649 ± 6618 pg/ml, respectively. A significantly
higher concentration of IFN-γ on ConA stimulated blood
was found when compared with LSA stimulated blood
(Wilcoxon signed-rank test: Z = -6.15, P <0.0001).
Dogs classified with stage I and IIa group presented
significantly higher (Mann-Whitney U-test: Z= -2.32, P=
0.02) LSA IFN-γ concentrations (mean±SD: 1939 ± 3952 pg/
ml) than dogs classified with stages IIb, III or IV group (mean
±SD: 411 ± 862 pg/ml) while no differences in ConA IFN-γ
concentrations were observed among these two groups.
IFN-γ producer dogs (n = 35) showed a significantly
higher (Mann-Whitney U-test: Z = -6.78, P < 0.0001) LSA
IFN-γ concentration (mean ± SD of 2320 ± 3961 pg/ml)
when compared with IFN-γ non-producers (n = 25)
(mean ± SD of 0 ± 0 pg/ml). The mean ± SD of ConA
IFN-γ concentration from IFN-γ producer dogs was
7887 ± 7273 pg/ml while the mean ± SD of ConA
IFN-γ concentration from IFN-γ non-producers was
4917 ± 5233 pg/ml. Statistical differences were found
between IFN-γ producers and non-producers for IFN-
γ concentration after stimulation with ConA (Mann-
Whitney U-test: Z = -2.04, P = 0.041).
Table 1 Clinicopathological findings in dogs with clinical leishmaniosis based on LeishVet clinical staging [6] (Continued)
Clinical staging Gender/median
[range] of age in
months
Serology Clinical signs (number of dogs/total
number of dogs, %)
Laboratory findings (number of dogs/
total number of dogs, %)
IV-very severe
disease (n = 4)





Weight loss (3/4, 75 %)
Cutaneous lesions (3/4, 75 %):
• Exfoliative dermatitis (2/4, 50 %)
• Ulcerative dermatitis (1/4, 25 %)
• Onicogriphosis (1/4, 25 %)
• Ulcerative and nodular blepharitis
(1/4, 25 %)
Vomiting and/or diarrhea (2/4, 50 %)
Lymphadenomegaly (1/4, 25 %)
Cachexy (1/4, 25 %)
Hypertension (1/4, 25 %)
Cardiac insufficiency (1/4, 25 %)
Keratoconjunctivitis (1/4, 25 %)
Chronic weakness (1/4, 25 %)
Paraparesis (1/4, 25 %)
Mild normocytic normochromic non
regenerative anemia (1/4, 25 %; 3/4, 75 %,
respectively)
Thrombocytosis (2/4, 50 %)
Lymphopenia (1/4, 25 %)
Mild leukocytosis with mature neutrophilia
(1/4, 25 %)
Total protein (4/4, 100 %)
Hypoalbuminemia ((4/4, 100 %)
Hypergammaglobulinemia (3/3, 100 %)
Hyperbetaglobulinemia (3/3, 100 %)
Proteinuria (UPC) (4/4, 100 %)
Renal azotemia (3/3, 100 %)
UPC: urinary protein creatinine ratio
Fig. 1 Percentages of sick dogs according with IFN-γ production after LSA stimulation and clinical staging. a IFN-γ producers (n = 35) and b IFN-γ
non-producers (n = 25)
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IL-10
The results of ConA and L. infantum specific IL-10 con-
centrations based on clinical staging and IFN-γ classifica-
tion are shown in Tables 2 and 3. The mean ± SD of IL-10
concentrations in supernatants of blood stimulated with
LSA and ConA from all dogs studied was 10 ± 15 pg/ml
and 83 ± 102 pg/ml, respectively. A significantly higher
concentration of IL-10 in ConA stimulated blood was
found when compared with LSA stimulated blood
(Wilcoxon signed-rank test: Z = -5.62, P < 0.0001). More-
over, 34 out of 53 dogs (64 %) did not produce IL-10 after
LSA stimulation (0 pg/ml) while the rest of the dogs
(n = 19; 36 %) produced significantly higher concen-
trations (Mann-Whitney U-test: Z = -6.46, P < 0.0001)
of IL-10 (mean ± SD of 27.1 ± 13.3 pg/ml). Only four
dogs did not produce IL-10 after ConA stimulation. Statis-
tical analysis showed significantly higher concentrations of
IL-10 in IFN-γ producer dogs after LSA stimulation when
compared with IFN-γ non-producers (Mann-Whitney U-
test: Z = -3.60, P < 0.0001). No significant differences in
IL-10 concentrations were observed after ConA stimula-
tion between IFN-γ producers and IFN-γ non-producers.
Concentration of IL-10 from dogs classified with stages
I and IIa group (10 ± 15 pg/ml) did not present significant
differences when compared with dogs classified with
stages IIb, III and IV group (10 ± 16 pg/ml). No differences
in ConA IL-10 concentrations were observed between
stage I and IIa group and stages IIb, III and IV group.
Correlation between parameters studied
The correlations among parameters studied are listed in
Table 4.
IFN-γ concentration after LSA stimulation was signifi-
cantly negatively correlated with blood PCR and anti-
body levels as well as positively correlated with IFN-γ
concentration after ConA stimulation and IL-10 concen-
tration after LSA stimulation. No further significant cor-
relations were found with IL-10 production.
Table 2 Summary of parameters studied based on clinical staging distribution of sick dogs
Clinical
staging
Mean ± standard deviation
Number of dogs IFN-γ LSA (pg/ml) IFN-γ ConA (pg/ml) IL-10 LSA (pg/ml) IL-10 ConA (pg/ml) PCR (parasite/ml) ELISA (EU)
I 10 2022 ± 2687h 4029 ± 3942i 17 ± 18 82 ± 46 3.7 ± 10.4d 46 ± 51a
IIa 27 1909 ± 4373 7943 ± 7115j 8 ± 14 57 ± 50 6 ± 10e 5533 ± 11338b
IIb 9 539 ± 1231 6777 ± 6068 7 ± 14 144 ± 130 101 ± 285f 23,287 ± 27636
III 10 423 ± 629 8004 ± 7914k 15 ± 19 94 ± 167 20 ± 26g 12,416 ± 20,227c
IV 4 94 ± 187 792 ± 350 5 ± 9 77 ± 112 6337 ± 12501 52,151 ± 44,365
Total 60 1354 ± 3220 6649 ± 6618 10 ± 15 83 ± 102 458 ± 3293 11,537 ± 22,240
Parameters under study were evaluated in relationship to clinical staging and letters from a to b correspond to statistically significant findings
Results for ELISA units aI < IIa, IIb, III, IV (Mann-Whitney U-test: Z = -3.7, P < 0.0001); bIIa > I (Mann-Whitney U-test: Z = -4.4, P < 0.0001) and IIa < IIb, IV (Mann-
Whitney U-test: Z = -2.7, P = 0.002); cIII < IV (Mann-Whitney U-test: Z = -2.1, P = 0.036)
Results for PCR dI < IV (Mann-Whitney U-test: Z = -2.8, P < 0,002); eIIa < IV (Mann-Whitney U-test: Z = -3.1, P < 0.0001); fIIb < IV (Mann-Whitney U-test: Z = -2.2,
P = 0.028); g III < IV (Mann-Whitney U-test: Z = -2.2, P = 0.024)
Results for IFN-γ LSA hI > IIb, III, IV (Mann-Whitney U-test: Z = -2.1, P < 0.035)
Results for IFN-γ ConA iI>IV (Mann-Whitney U-test: Z = -2.1, P = 0.036); jIIa > IV (Mann-Whitney U-test: Z = -2.7, P = 0.003); kIII > IV (Mann-Whitney U-test:
Z = -2.5, P = 0.008)
Abbreviations: LSA L. infantum soluble antigen, ConA concavalin A
Table 3 Summary of parameters based on IFN-γ producer versus IFN-γ non-producer dogs
Clinical
staging


















I 9 2247 ± 2749 18 ± 20 4.1 ± 11 50 ± 53 1 0 ± 0 15 ± 0 0 ± 0 13 ± 0
IIa 17 3031 ± 5240 12 ± 16 2 ± 4 2660 ± 7140 10 0 ± 0 3 ± 8 12 ± 14 10,418 ± 15,420
IIb 3 1616 ± 1860 14 ± 23 0.1 ± 0.1 14,373 ± 15,473 6 0 ± 0 3.3 ± 8 162 ± 360 27,744 ± 32,476
III 5 846 ± 665 29 ± 18 12 ± 19 7755 ± 5590 5 0 ± 0 0 ± 0 29 ± 31 17,077 ± 28,897
IV 1 375 ± 0 19 ± 0 35 ± 0 73,701 ± 0 3 0 ± 0 0 ± 0 8438 ± 14,419 44,967 ± 51,408
Total 35 2320 ± 3961a 16 ± 18b 5 ± 10 5750 ± 14,082 25 0 ± 0 2.4 ± 7 1100 ± 5112c 19,638 ± 28,596d
Statistical study was performed to compare IFN-γ producers versus non-IFN-γ producers. Letters a to d correspond to statistically significant differences
Results for IFN-γ LSA, IFN-γa producers > non-IFN-γ producers (Mann-Whitney U-test: Z = -6.7, P < 0.0001)
Results for IL-10 LSA, IFN-γb producers > non-IFN-γ producers (Mann-Whitney U-test: Z = -3.60, P < 0.0001)
Results for PCR, IFN-γc producers< non-IFN-γ producers (Mann-Whitney U-test: Z = -3.2, P = 0.001)
Results for ELISA units, IFN-γd producers< non-IFN-γ producers (Mann-Whitney U-test: Z = -3.2, P = 0.001)
Abbreviations: LSA L. infantum soluble antigen
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Discussion
In the present study, we demonstrated, for the first time,
that dogs with several clinical stages of leishmaniosis
presented differences in L. infantum specific cytokine
profiles in stimulated blood. Interestingly, more than
half of the dogs with clinical leishmaniosis showed a
marked L. infantum specific IFN-γ production. Canine
clinical leishmaniosis is classically characterized by a re-
duced or absent L. infantum specific T-cell mediated im-
munity [25]. In contrast, Leishmania-specific IFN-γ
production in stimulated blood in dogs [26, 27] and
other mammals such as rodents and humans have been
associated with a resistant phenotype or with animals
able to control infection [9]. However, more recent
studies have already highlighted that T-cell mediated
immunity might also be observed in dogs with clinical
illness [28, 29] in agreement with the present results.
It is also important to remark that the majority of dogs
(58 %) that were L. infantum specific IFN-γ producers
were also classified with the lower clinical stages and
were mainly classified as having stage I or stage IIa [6].
Furthermore, significant higher L. infantum IFN-γ con-
centration was noted between stage I and IIa group and
stage IIb, III and IV group. In addition, IFN-γ producer
dogs presented lower antibody levels as well as lower
blood parasitemia when compared with IFN-γ non-
producers. Moreover, significant negative correlations
were found between LSA IFN-γ concentration and anti-
body and blood parasitemia. Similar findings were ob-
served in Brazil where pro-inflammatory cytokines such
as IFN-γ and TNF-α were highly expressed in the spleen
of naturally infected dogs with low parasitism and these
cytokines were negatively correlated with the parasite
burden in the spleen [29]. An experimental canine
model also demonstrated that splenic parasite burdens
correlated negatively with Leishmania-specific IFN-γ
and IL-2 levels, and negatively with leishmanin skin test
reactivity [30].
In the present study, 42 % of the dogs were IFN-γ
non-producers and these dogs were most likely to be
classified in higher clinical stages (stage IIb, III and IV)
and also had high specific positive antibody levels and
blood parasitemia as previously described in other stud-
ies in dogs with severe clinical leishmaniosis [19, 31]. It
has been previously demonstrated that as dogs progress
to clinical leishmaniosis, they display impaired CD4+ T
cell proliferation and IFN-γ production ex vivo in re-
sponse to L. infantum antigen [19, 31]. However, the cel-
lular basis and mechanisms for the development of
antigen specific T-cell unresponsiveness in canine leish-
maniosis are not fully understood. T cell exhaustion is
well documented in chronic infections such as parasitic
infections in several mammals. T cell exhaustion is
defined as antigen-specific effector T cell dysfunction
with sustained expression of inhibitory receptors, in-
cluding programmed cell death protein 1 (PD-1) and
decreased effector cytokine production such as IFN-γ
[32, 33]. Interestingly, T cell exhaustion was significantly
associated with a four-fold increase in the population of
T cells (both CD4+ and CD8+ T cells) with PD-1 in a
study comparing healthy non-infected control and sick
foxhounds dogs with clinical leishmaniosis [31]. This
was in conjunction with an absent lymphocyte prolifera-
tion and decreased peripheral blood mononuclear cells (
PBMC) L. infantum specific IFN-γ production. These
authors also demonstrated that PD-1 mediated exhaus-
tion influenced macrophage-reactive oxygen intermedi-
ate production enabling the control of Leishmania
infection [31]. We believe that T-cell exhaustion is prob-
ably the mechanism that explains L. infantum antigen T-
cell unresponsiveness in our patients with moderate to
very severe disease. Further studies should elucidate if
PD-1 is diversely expressed in dogs in different clinical
stages as the ones described in the present study.
Furthermore, in this study we have demonstrated that
there were significant differences in IFN-γ production
after stimulation with ConA among clinical stages as
well as between IFN-γ producer and non-producer dogs.
In stage IV-very severe disease, the IFN-γ concentration
after stimulation with ConA was significantly lower than
in other less severe clinical stages (I, IIa and III) and the
same tendency was noted with dogs in stage IIb. In
addition, IFN-γ non-producer dogs showed significantly
lower IFN-γ concentration after stimulation with ConA
when compared with IFN-γ producer dogs. These find-
ings demonstrate that dogs with very severe disease are
in more T cell anergy than dogs with less severe clinical
stages. This was previously demonstrated by means of
mitogenic lymphocyte proliferation such as conA in
dogs with clinical leishmaniosis [34, 35].
Interestingly, our findings of IL-10 are not in agree-
ment with the majority of studies on human visceral
Table 4 Correlation between IFN-γ concentration after LSA
stimulation and the level of antibodies, blood parasitemia and
cytokine production
Parameter (units) Spearman’s correlation
coefficient (rS)
P-value
L. infantum specific antibody
levels (EU)
-0.391 0.002










Abbreviations: LSA L. infantum soluble antigen, ConA concavalin A
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leishmaniosis [36, 37] or other studies reported in dogs
with clinical leishmaniosis where a low or absent IFN-γ
production was found in tandem with increased produc-
tion of IL-10 [19, 29]. An experimental canine model
also demonstrated that splenic parasite burdens corre-
lated positively with Leishmania-specific IL-10 levels
[30]. Interestingly, a recent study carried out in Ethiopia
in humans with visceral leishmaniosis due to L. donovani
showed that Leishmania stimulated whole blood cells
produce low or levels below the detection limit of IFN-γ
and IL-10 [38] in agreement with the results of IFN-γ
non-producer dogs of this study. In the present study,
IFN-γ producer dogs secreted higher levels of IL-10 con-
centration after LSA stimulation when compared with
IFN-γ non-producers. The reasons for these findings are
difficult to explain but it could be because after LSA
stimulation, IFN-γ non-producer dogs might be less re-
sponsive to other cytokines including IL-10. Another
possibility could be that IL-10 is produced in IFN-γ pro-
ducer dogs as a negative feedback to control proinflamma-
tory cytokines as described in human mucocutaneous
leishmaniosis [39]. IL-10 can counterbalance the proin-
flammatory effect of IFN-γ, leading to an adequate regula-
tion of immune responses. In addition, it is important to
remark that a high proportion of dogs did not produce IL-
10 and that, in general, IL-10 concentration was extremely
much lower than IFN-γ concentration. Moreover, IL-10
concentration after LSA stimulation was not associated
with disease severity. Therefore, IL-10 does not appear to
be a marker of disease severity.
Suppressed cell-mediated immunity in clinical canine
leishmaniosis as a result of the inability of PBMCs to re-
spond to Leishmania antigen, is thought to underlie the
progressive nature of this disease [9]. In the present
study, we reported the ability of a whole blood IFN-γ re-
lease assay to detect dogs with clinical leishmaniosis
with moderate to severe disease as previously reported
in humans with visceral leishmaniosis due to L. donovani
[40–43]. To date, there are few and poorly standardized
assays to evaluate L. infantum specific T-cell mediated
immunity responses in dogs [13] such as the leishmanin
skin test [14, 15], lymphocyte proliferation assays [16,
17] and cytokine profiles in stimulated PBMC or blood
from dogs [44, 45]. This type of L. infantum specific
whole blood assay has been described before in Leish-
mania vaccinated dogs [44, 45]. However, to the best
knowledge of the authors, this is the first time, that this
whole blood assay has been performed in dogs with clin-
ical leishmaniosis at different clinical stages. In human
visceral leishmaniosis, whole blood assay that uses
soluble Leishmania antigen have shown advantages
over the leishmanin skin test, in terms of higher specifi-
city and better correlation with surrogate markers of
exposures to L. donovani [43]. Furthermore, in humans,
CD4+ T cells were found to be crucial for and the main
source of the IFN-γ production in Leishmania stimulated
whole blood cultures [42] and we postulated that the same
occurs in canines. We believe as described in human vis-
ceral leishmaniosis [43], that this assay is a promising tool
to evaluate cellular immune responses in dogs in endemic
areas. Research in this area is essential for the develop-
ment of potential immunological and epidemiological
tools for both canine and human leishmaniosis.
Our findings confirmed that canine leishmaniosis
manifests in a wide spectrum of clinical illness as well
documented elsewhere in clinical cases [46], studies [47]
and guidelines [6, 48]. The majority of dogs (60 %) were
classified as LeishVet stage II (moderate disease) fol-
lowed by stages I (16 %), III (16 %) and IV (6.6 %). In
addition, stage IIa (45 %) was the most frequently diag-
nosed clinical stage in the present study. The present re-
sults gave a good picture of the current presentation of
clinical canine leishmaniosis at least in the north-east of
Spain in client-owned dogs based on clinical stages. Our
findings are likely to be similar to those present in other
Mediterranean countries such as Portugal, France or
Italy. It is important to highlight that the majority of the
dogs studied did not have evidence of renal disease and,
therefore, they had a good prognosis if managed with
anti-Leishmania treatment.
Conclusions
The results of this study demonstrate that sick dogs lack-
ing L. infantum specific IFN-γ production in stimulated
whole blood produce a strong humoral response, have a
high blood parasitemia and severe clinical disease. In
contrast, IL-10 does not appear to be a marker of disease
severity. Pinpointing the precise immune responses asso-
ciated with canine leishmaniosis will help to advance
treatment and the development of a preventative strategy.
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